Open Access
Cannabidiol use and perceptions in France: a national survey
Clémence Casanova
1
,
Clémence Ramier
1
,
Davide Fortin
2
,
Patrizia Carrieri
1
,
Julien Mancini
1, 3
,
Tangui Barré
1
1
2
Sorbonne Economics Centre, University, Paris, France
|
3
Public Health Department, APHM, BIOSTIC, Marseille, France
|
Publication type: Journal Article
Publication date: 2022-08-29
scimago Q1
wos Q1
SJR: 1.359
CiteScore: 6.0
Impact factor: 3.6
ISSN: 14712458
PubMed ID:
36038869
Public Health, Environmental and Occupational Health
Abstract
Cannabidiol (CBD), a safe, non-intoxicating cannabis component, is growing in popularity in Europe and worldwide. However, CBD EU regulation is blurry, and consequent labelling and product quality issues may have implications for public health. There is therefore a need to assess the prevalence and perceived harmfulness of CBD use in EU countries, as well as to characterise CBD users. We aimed to do so in the French population. In December 2021, an online survey was conducted in a sample respecting the French adult population structure for key demographic variables. Sociodemographic, behavioural and CBD perception data were collected. Three separate regressions were performed to identify correlates of i) having heard of CBD, ii) using CBD, iii) perceived harmfulness of CBD. A hierarchical classification was also performed to identify profiles of CBD users. The study sample comprised 1969 adults, of whom 69.2% had heard of CBD and 10.1% used it. Less than half (46.8%) of the former considered it harmful. Having heard of CBD was associated with younger age, being born in France, tobacco use, and cannabis use. CBD use was associated with younger age, tobacco use, cannabis use, poor self-reported general health status, and positive perception of alternative medicines. Cluster analysis revealed four different CBD user profiles based on socio-demographics and behavioural characteristics. Ten percent of the adults in this French study used CBD, and several user profiles emerged. Our results indirectly advocate clearer European CBD regulations to ensure safe and high-quality products.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Drug and Alcohol Review
3 publications, 13.64%
|
|
|
Regulatory Toxicology and Pharmacology
1 publication, 4.55%
|
|
|
Journal of Psychoactive Drugs
1 publication, 4.55%
|
|
|
Molecules
1 publication, 4.55%
|
|
|
BMC Public Health
1 publication, 4.55%
|
|
|
Pharmacy
1 publication, 4.55%
|
|
|
Frontiers in Pharmacology
1 publication, 4.55%
|
|
|
Therapie
1 publication, 4.55%
|
|
|
Obstetrics and Gynecology
1 publication, 4.55%
|
|
|
International Journal of Cancer
1 publication, 4.55%
|
|
|
International Journal of Drug Policy
1 publication, 4.55%
|
|
|
Pain and Therapy
1 publication, 4.55%
|
|
|
iScience
1 publication, 4.55%
|
|
|
Clinical Parkinsonism & Related Disorders
1 publication, 4.55%
|
|
|
International Journal of Mental Health and Addiction
1 publication, 4.55%
|
|
|
Translational Vision Science and Technology
1 publication, 4.55%
|
|
|
International Journal of Environmental Research and Public Health
1 publication, 4.55%
|
|
|
Parkinson's Disease
1 publication, 4.55%
|
|
|
Veterinary Journal
1 publication, 4.55%
|
|
|
Expert Review of Neurotherapeutics
1 publication, 4.55%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
|
|
|
Elsevier
6 publications, 27.27%
|
|
|
Wiley
4 publications, 18.18%
|
|
|
MDPI
3 publications, 13.64%
|
|
|
Springer Nature
3 publications, 13.64%
|
|
|
Taylor & Francis
2 publications, 9.09%
|
|
|
Frontiers Media S.A.
1 publication, 4.55%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 4.55%
|
|
|
Association for Research in Vision and Ophthalmology (ARVO)
1 publication, 4.55%
|
|
|
Hindawi Limited
1 publication, 4.55%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
22
Total citations:
22
Citations from 2024:
16
(72.72%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Casanova C. et al. Cannabidiol use and perceptions in France: a national survey // BMC Public Health. 2022. Vol. 22. No. 1. 1628
GOST all authors (up to 50)
Copy
Casanova C., Ramier C., Fortin D., Carrieri P., Mancini J., Barré T. Cannabidiol use and perceptions in France: a national survey // BMC Public Health. 2022. Vol. 22. No. 1. 1628
Cite this
RIS
Copy
TY - JOUR
DO - 10.1186/s12889-022-14057-0
UR - https://doi.org/10.1186/s12889-022-14057-0
TI - Cannabidiol use and perceptions in France: a national survey
T2 - BMC Public Health
AU - Casanova, Clémence
AU - Ramier, Clémence
AU - Fortin, Davide
AU - Carrieri, Patrizia
AU - Mancini, Julien
AU - Barré, Tangui
PY - 2022
DA - 2022/08/29
PB - Springer Nature
IS - 1
VL - 22
PMID - 36038869
SN - 1471-2458
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Casanova,
author = {Clémence Casanova and Clémence Ramier and Davide Fortin and Patrizia Carrieri and Julien Mancini and Tangui Barré},
title = {Cannabidiol use and perceptions in France: a national survey},
journal = {BMC Public Health},
year = {2022},
volume = {22},
publisher = {Springer Nature},
month = {aug},
url = {https://doi.org/10.1186/s12889-022-14057-0},
number = {1},
pages = {1628},
doi = {10.1186/s12889-022-14057-0}
}